Scientific Advisory Board

Michael Gilman, PhD

Michael Gilman, PhD

Michael is CEO of Arrakis Therapeutics. In addition, Mike currently serves on the Boards of Directors of Novartis Venture Fund, Obsidian Therapeutics, and Scholar Rock (NASDAQ: SRRK) and on the Scientific Advisory Board of FutuRx. Previously, Mike was Chief Executive Officer of Obsidian Therapeutics, a venture-funded company focused on applying synthetic biology to gene and…
more
Steve Hitchcock, PhD

Steve Hitchcock, PhD

Dr. Steve Hitchcock is Head of Research for Takeda Pharmaceutical Company, Ltd.  He joined Takeda in 2012 via Takeda’s acquisition of Envoy Therapeutics where he was Senior Vice President of Drug Discovery and also held the position of Adjunct Professor at The Scripps Research Institute. Prior to Takeda, Dr. Hitchcock had served in senior leadership…
more
Nissim Darvish, MD, DSc

Nissim Darvish, MD, DSc

Nissim Darvish, M.D., Ph.D., is a Venture Partner  at OrbiMed Advisors. Nissim is a veteran of the lifescience industry, with 25 years of experience covering medical technology development, corporate leadership and investment management. Nissim spent eight years with Pitango, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and…
more
John Isaac, PhD

John Isaac, PhD

John is Senior Director, Neuroscience External Innovation at Johnson & Johnson Innovation, London.  In this role John uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer’s Disease and Mood Disorders. Prior to joining Johnson & Johnson, since November 2014, John was Head of Neuroscience and Mental…
more
Scott Fields, MD

Scott Fields, MD

Dr. Scott Z. Fields is Senior Vice President Head Pharmaceutical Development Oncology at Bayer. Scott Fields, M.D., joined Bayer from Vertex Pharmaceuticals, where he was vice president and head of Clinical Oncology and responsible for the global development of all oncology assets. Prior to joining Vertex, he held a number of leadership roles within the pharmaceutical…
more
Tetsuyuki Maruyama, PhD

Tetsuyuki Maruyama, PhD

Tetsuyuki Maruyama is Executive Director at Alzheimer’s Disease Data Initiative, a non-profit organization dedicated to sharing data relevant to Alzheimer’s disease and other dementias.  Prior to that he served as Chief Scientific Officer at The Dementia Discovery Fund, a specialist venture capital fund. Tetsu’s background is in neuroscience, having received his PhD from Stanford University…
more
Dror Haratz, MD

Dror Haratz, MD

Prof. Harats is CEO and Director at VBL Therapeutics. Prof. Harats has more than 20 years of experience in research in the field of medicine and biotechnology, as well as a strong background in management of early- to mid-stage biotechnology companies.  He is also a professional and experienced consultant specializing in Biotechnology/Pharmaceutical healthcare companies. A professor…
more
Michal Preminger, PhD, MBA

Michal Preminger, PhD, MBA

Michal is Head of Johnson & Johnson Innovation, East North America, located at the Innovation Centre in Boston.  In this role she leads the Innovation Center team to build, advance, and manage the External R&D portfolio of co-investments spanning across pharmaceutical, consumer health and medical devices. Until recently, Michal served as the Executive Director of Harvard…
more
Marie A. Lindner, MD

Marie A. Lindner, MD

Marie Lindner, MD worked in executive roles in pharmaceutical, biotech, venture capital, start-up and medtech companies with experience across therapeutic areas and modalities and between business and clinical development over 30 years.  She was most recently recruited to start a team at Novartis Pharmaceuticals, focused on finding new trends in science and medicine.  Dr. Lindner…
more
Bernhard Kirschbaum, PhD

Bernhard Kirschbaum, PhD

Bernhard Kirschbaum, PhD, studied and spent his early career as a researcher in biochemistry and physiological chemistry at the University of Konstanz, Germany, receiving his PhD in 1989. He moved on to work at the Rockefeller University in New York and the Pasteur Institute in Paris. Subsequently, he joined the pharmaceutical industry where he covered…
more
Font Resize
Contrast